1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Chongqing Jiheng Pharmaceutical Co., Ltd. Class A

Chongqing Jiheng Pharmaceutical Co., Ltd. Class A

SSZSE:002742
3.63
CNY
+0.04
(+1.11%)
-0.56EPS
2.29BMarket Cap
Chongqing Jiheng Pharmaceutical Co., Ltd. Class A
SZSE:002742
(Shenzhen Stock Exchange)

Recent

price

3.63

P/E

ratio

- -

div

yld

0.67%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.61
3.27
3.61
3.94
3.42
3.46
4.43
6.63
7.36
5.9
5.76
4.84
4.72
1.75
1.31
1.05
Revenue per Share
0.27
0.32
0.32
0.31
0.29
0.27
0.42
0.26
0.29
0.17
-0.77
-0.74
-1.05
-0.95
-0.61
-0.5
Basic EPS, GAAP
-0.06
-0.03
-0.46
-0.5
-0.22
-0.28
-0.3
-0.67
-0.59
0.11
0.09
0.01
-0.23
-0.15
-0.05
- -
Free Cash Flow per Basic Share
0.03
0.04
0.11
0.15
0.11
0.16
0.19
0.29
0.31
0.29
0.34
0.15
0.05
0.01
0.02
0.02
Dividend per Share
1.23
1.56
1.83
2.11
2.83
3.02
3.28
3.49
3.6
3.51
2.59
1.86
0.8
-0.95
0.25
0.22
Book Value per Share
1.07
1.39
1.68
1.91
2.66
2.19
1.58
1.71
1.69
1.54
0.79
-0.03
-1.02
-2.24
-0.22
-0.24
Tangible Book Value per Share
324
325
325
323
413
437
429
432
432
432
432
430
431
684
688
621
Basic Weighted Avg Shares
848
1,062
1,174
1,271
1,411
1,513
1,902
2,865
3,180
2,550
2,489
2,077
2,030
1,196
900
655
Sales/Revenue/Turnover
13.2
12.54
12.12
12.53
13.16
13.14
11.62
12.66
10.54
10.31
3.49
2.41
4.27
-4.64
-11.02
-9.47
Operating Margin (%)
42
42
48
64
69
77
124
149
165
160
149
132
126
114
93
- -
Depreciation Expense
87
102
103
101
122
118
180
111
125
73
-333
-318
-452
-650
-420
-311
Net Income, GAAP
15.08
15.05
15.73
15.36
14.24
16.01
11.76
18.15
14.91
25.33
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
10.29
9.65
8.74
7.95
8.63
7.79
9.48
3.87
3.93
2.88
-13.4
-15.3
-22.27
-54.37
-46.64
-47.45
Profit Margin (%)
48
137
174
222
512
200
467
596
-487
-291
-662
-1,163
-1,460
-1,628
72
75
Working Capital
- -
- -
59
40
- -
135
977
886
68
268
268
- -
- -
- -
444
444
LT Debt
399
504
595
688
1,231
1,353
1,634
1,756
1,807
1,756
1,313
992
558
-229
239
219
Total Equity
- -
14.38
10.71
10.09
9.43
6.48
7.21
4.49
4.58
2.84
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
16.86
14.24
13.01
11.05
7.89
8.79
6.03
6.71
5.67
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
22.7
18.68
15.84
12.77
9.33
13.26
7.58
8.15
4.78
-25.29
-33.06
-78.78
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
82
86
39
LT Borrowings
444
444
444
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
684
684
684
Market Capitalization
3,092
3,058
2,292

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
393
337
318
Cash, Cash Equivalents & STI
114
51
42
Accounts Receivable, Net
106
115
122
Inventories
158
154
141
Total Current Liabilities
321
260
243
Payables & Accruals
- -
- -
- -
ST Debt
82
86
39
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-40.08%
-87.8%
-204.49%
Free Cash Flow
-224.03%
-454.09%
-66.53%
Net Income, GAAP
-52.54%
-101.63%
-35.45%
Sales/Revenue/Turnover
-1.23%
-17.4%
-24.74%
Total Cash Common Dividend
6.3%
-12.32%
104.32%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
348
388
251
209
1,196
2025
235
251
- -
163
900
2026
142
99
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.08
-0.07
0.06
-1.41
-0.95
2025
-0.19
-0.11
- -
-0.35
-0.61
2026
-0.01
-0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.01
2025
- -
0.09
- -
-0.04
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
Dow Inc. (NYSE:DOW)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
Business
Chongqing Sansheng Industrial Co., Ltd. (002742.SZ) is a China-based diversified company principally engaged in the research, development, production and sale of building materials, chemicals and pharmaceuticals, with a focus on comprehensive utilization of gypsum resources; its core products include commercial concrete, water reducing agents, expansion agents, sulfuric acid, pharmaceutical intermediates, active pharmaceutical ingredients and finished pharmaceutical products for applications in industrial and civil construction, highways, bridges, tunnels and healthcare sectors. Founded in 2002 and headquartered at No. 99, Yunhan Avenue, Water and Soil High-tech Industrial Park, Liangjiang New Area, Chongqing, the company operates primarily in China with international sales activities and maintains industrial-scale operations in mining development, chemical manufacturing and pharmaceutical production. Recent developments include signing a restructuring investment framework agreement on October 31, 2024, with Jiheng Group, Shenzhen High-tech Investment and Chongqing Leiden; executing a debt settlement agreement on December 18, 2024, with Shenzhen High-tech Investment Group to offset 201 million yuan in liabilities using prepaid balances; and facing a delisting risk warning following disclosure of its 2024 annual report, which projects net losses amid declines in domestic building materials, pharmaceuticals and overseas currency impacts.